Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 and CD22 targeted prime CAR-T cells
- Development stage
- Phase 2
- Lead developer
- Chongqing Precision Biotech Co., Ltd
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CD19 and CD22 targeted prime CAR-T cells is an autologous, dual-targeted chimeric antigen receptor (CAR) T-cell therapy developed by Chongqing Precision Biotech Co., Ltd. It simultaneously targets CD19 and CD22, two antigens frequently expressed on B-cell malignancies, to mitigate the risk of antigen escape and subsequent relapse. The therapy is manufactured using the company's proprietary **PrimeCAR** platform, which utilizes a rapid manufacturing process (approximately 48 hours) characterized by mild activation and shortened in vitro expansion. This approach is designed to preserve T-cell stemness and improve long-term persistence and efficacy while potentially reducing manufacturing costs and time-to-treatment. It is currently being evaluated in Phase 1/2 clinical trials for the treatment of relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukemia (B-ALL).
- Other names
- CD19/CD22 dual-targeted PrimeCAR-T cellsCD19 and CD22 targeted prime CAR- T cellsCD-19 and CD22 targeted prime CAR- T cellsCD 19 and CD22 targeted prime CAR- T cells
02
Targets
CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)
Beyond the preview
Go deeper on CD19 and CD22 targeted prime CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 and CD22 targeted prime CAR-T cells.